Scarica l'app Stockscreener
44.34
0.36%
-0.16
Dopo l'orario di chiusura:
45.00
0.66
+1.49%
Precedente Chiudi:
$44.50
Aprire:
$44.59
Volume 24 ore:
1.71M
Relative Volume:
1.02
Capitalizzazione di mercato:
$5.80B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-9.6391
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
-3.98%
1M Prestazione:
-8.93%
6M Prestazione:
+28.30%
1 anno Prestazione:
-49.45%
Intervallo 1D:
$43.34
$44.78
Intervallo di 1 settimana:
$42.55
$46.44
Portata 52W:
$27.66
$93.77
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
44.34 | 5.83B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-12 | Iniziato | Goldman | Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors - Yahoo Finance
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension - MSN
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Trading Systems Reacting to (PCVX) Volatility - news.stocktradersdaily.com
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com Canada
Vaxcyte Finalizes Trial Design for VAX-31, Aiming to Set New Standard for Adult Pneumococcal Vaccines in Consultation with FDA - Quiver Quantitative
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - The Manila Times
Vaxcyte Doses First Participants in the OPUS Phase 3, - GlobeNewswire
Jump Financial LLC Has $13.12 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Norges Bank Acquires Shares of 987,674 Vaxcyte, Inc. $PCVX - MarketBeat
Walleye Capital LLC Grows Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (BIT:1PCVX) Price Target Increased by 17.53% to 85.05 - Nasdaq
Vaxcyte (NASDAQ:PCVX) Trading Down 3.7%Here's Why - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Saturn V Capital Management LP - MarketBeat
American Century Companies Inc. Sells 236,002 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
JPMorgan Chase & Co. Decreases Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (NASDAQ:PCVX) Shares Gap DownHere's What Happened - MarketBeat
Can Vaxcyte Inc. (5VA) stock attract analyst upgrades2025 Technical Patterns & Growth Focused Stock Pick Reports - Newser
Quadrature Capital Ltd Takes $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Is Vaxcyte Inc. (5VA) stock a top hedge fund pickJuly 2025 Short Interest & Low Risk High Reward Ideas - Newser
Transcript : Vaxcyte, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02 - marketscreener.com
Transcript : Vaxcyte, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 02 - marketscreener.com
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Cipher Mining Lag - Barron's
XTX Topco Ltd Has $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
Franklin Resources Inc. Lowers Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
DNB Asset Management AS Acquires 6,924 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Entropy Technologies LP Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
Why Vaxcyte Inc. (5VA) stock remains stableJuly 2025 Closing Moves & Short-Term High Return Ideas - BỘ NỘI VỤ
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cash per share of Vaxcyte, Inc. – BX:PCVX - TradingView
8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP - MarketBeat
Vaxcyte, Inc. $PCVX Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Intech Investment Management LLC Sells 19,443 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
EBIT per share of Vaxcyte, Inc. – DUS:5VA - TradingView
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):